<code id='46384BDC73'></code><style id='46384BDC73'></style>
    • <acronym id='46384BDC73'></acronym>
      <center id='46384BDC73'><center id='46384BDC73'><tfoot id='46384BDC73'></tfoot></center><abbr id='46384BDC73'><dir id='46384BDC73'><tfoot id='46384BDC73'></tfoot><noframes id='46384BDC73'>

    • <optgroup id='46384BDC73'><strike id='46384BDC73'><sup id='46384BDC73'></sup></strike><code id='46384BDC73'></code></optgroup>
        1. <b id='46384BDC73'><label id='46384BDC73'><select id='46384BDC73'><dt id='46384BDC73'><span id='46384BDC73'></span></dt></select></label></b><u id='46384BDC73'></u>
          <i id='46384BDC73'><strike id='46384BDC73'><tt id='46384BDC73'><pre id='46384BDC73'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:6679

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia